VIGIL is the first immunotherapy trial designed specifically for Ewing sarcoma patients. A new cohort to the EWING VIGIL VACCINE TRIAL has recently opened and is recruiting patients at Mary Crowley, Cleveland Clinic and Memorial Sloan Kettering.
Click here to learn more:
Rutledge Cancer Foundation is a 501(c)(3) Public Charity Under Federal Tax Guidelines
Tax ID 27-5035852
Financial Accountability
5608 Malvey Ave., Suite 306, Fort Worth, Texas
Copyright 2022 © All rights Reserved. Design by Metamedia Creative Co.
